Cochlear swings to loss on court costs and Covid
Hearing implant maker Cochlear has posted a $238.3m loss after elective surgery cancellations and US litigation expenses wiped out profits.
Hearing implant maker Cochlear has posted a $238.3m loss after elective surgery cancellations and US litigation expenses wiped out profits.
Estia’s Victorian nursing homes are under strict controls after a third were infected with COVID, fuelling $144m in writedowns.
A conga-line of copycats are looking to lap up A2 Milk’s cream, but chairman David Hearn has declared the company can become the Dyson of dairy.
CSL confirms it is in talks with British pharmaceutical giant AstraZeneca about producing its vaccine in Melbourne.
Shares in Australian biotech Mesoblast rocket after it clears first approval hurdle for its drug to treat patients with serious COVID-19 complications.
CEOs say virus is here to stay until a vaccine is fully developed.
Victorian truckies are increasingly refusing to drive to South Australia over the state’s “unworkable” forced COVID-19 tests.
AMA wants to ensure clinical independence to avoid a US-style model where health insurers have a greater say over patient care.
David Bortolussi is returning to the food and beverage sector after being announced as A2 Milk’s third CEO in a year.
Shares in Mesoblast sank over 20pc after US authorities raised concerns about the effectiveness of its COVID-19 treatment.
Original URL: https://www.theaustralian.com.au/author/jared-lynch/page/193